Sitemap > News > Pain
- Progenics and Wyeth Announce FDA Has Accepted for Filing the New Drug Application for Subcutaneous Methylnaltrexone
- Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
- ROXRO PHARMA’s novel intranasal pain reliever effective, well tolerated in phase 3 study
- NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting
- AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
- FROVA Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
- Penwest Begins Dosing Phase IIa Clinical Study of Nalbuphine ER
- WEX Receives No Objection Letter from Health Canada for Phase III Clinical Trial in Cancer Pain
- DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
- Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
- Acura Pharmaceuticals, Inc. and FDA Reach Agreement on Special Protocol Assessment for Pivotal Phase 3 Study for OxyADF Tablets
- Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
- Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
- YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF
- DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
- Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET(R) at International Myeloma Workshop
- NicOx initiates third pivotal naproxcinod phase 3 study
- Newron Reports Positive Phase Ii Results For Ralfinamide In Neuropathic Pain
- Labopharm meets with FDA to discuss second Approvable Letter for once-daily tramadol
- Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
- BEMA Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA
- DEPOMED ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIAL FOR GABAPENTIN GR(TM) IN POSTHERPETIC NEURALGIA
- Patient Recruitment Completed for Pivotal Phase III Study of Remoxy
- Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
- YM BIOSCIENCES ANNOUNCES SECONDARY EFFICACY AND SAFETY FINDINGS IN RANDOMIZED PHASE IIB AEROLEF™ TRIAL
- DURECT Reports Positive Results from POSIDUR Phase IIb Hernia Trial, Triggering $8 million Milestone Payment from Nycomed
- Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
- EpiCept Announces Phase III Study of EpiCept NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- Javelin Pharmaceuticals Initiates Phase 3 Breakthrough Cancer Pain Trial for Intranasal Ketamine
- FDA issues second approvable letter for Trexima
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1
- NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine
- Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
- Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
- New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression
- Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic Pain
- DIAMYD UPDATES GENE THERAPY PROGRAM AND OUTLINES PLANS FOR PHASE I CLINICAL TRIAL FOR TREATMENT OF CANCER PAIN
- TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
- Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
- Biovail Receives Canadian Approval for Ralivia
- NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
- AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
- XTL BIOPHARMACEUTICALS INITIATES PHASE IIB CLINICAL TRIAL OF BICIFADINE FOR THE TREATMENT OF DIABETIC NEUROPATHIC PAIN
- Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol)
- Wyeth and Progenics Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
- Quigley Corporation Releases Update on Quigley Pharma’s Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
- Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
- Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
- Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
- Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
- Sucampo Pharmaceuticals Initiates Phase 2, Dose-Finding Trial of Cobiprostone for the Prevention of NSAID-Induced Ulcers in Arthritis Patients
- NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
- Phase 1 transdermal oxycodone clinical trial approved
- Labopharm provides update on U.S. regulatory process for once-daily Tramadol
- FDA Warns of Potential Serious Side Effects with Breakthrough Cancer Pain Drug
- NeurogesX\' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
- Endo Pharmaceuticals and Vernalis Receive Action Letter From FDA on FROVA(R) Supplemental New Drug Application
- Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
- Horizon TherapeuticsInitiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
- Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
- POZEN Submits Response to Approvable Letter for Trexima
- Alpharma Presents Positive Results from a Phase 2 Study of the Investigational Abuse-Deterrent Opioid ALO-01
- Labopharm appeals FDA\'s decision on once-daily tramadol
- Wyeth and Progenics to Initiate Phase 2 Trials of Oral Methylnaltrexone in Chronic-pain Setting
- Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
- Innocoll Files Investigational New Drug Application for its CollaRx® BUPIVACAINE TOPICAL for the Treatment of Painful Chronic Skin Ulcers and Burns
- Adolor Corporation Initiates Second Phase 2 Study of Novel Delta Agonist
- Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
- Orphan Australia receives registration approval for the new dose form DepoDur™ modified release injection of morphine sulfate
- The NDA for BEMA Fentanyl submitted in the US
- Avigen\'s AV411 Shows Promising Initial Results for Neuropathic Pain
- Pozen Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
- Neuromed Initiates Pivotal Phase 3 Clinical Trial of NMED-1077 for Chronic Pain
- Endo announces update on Phase III-program for Orexo´s pain product Rapinyl
- SCOLR Pharma, Inc. Initiates Pivotal Trials for 12-hour Ibuprofen
- NSL-101 Phase II Clinical Trial Receives Approval
- Cephalon Submits Supplemental New Drug Application for FENTORA
- Array BioPharma Advances p38 Inhibitor, ARRY-797, into Phase 2 Clinical Trial
- Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
- Biovail Confirms FDA Class 2 Status For BVF-033 Submission
- Sosei Announces Update on Phase I Trials for SD118
- Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
- Valeant Pharmaceuticals Starts Phase 2 Retigabine Study for Treatment of Postherpetic Neuralgia
- UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
- Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain
- Patient Enrollment Completed in Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy
- Targacept Announces Results of Phase II Study of TC-2696 in Postoperative Dental Pain
- Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
- Cannasat and IntelGenx Complete Phase 1 Study for CAT 310
- Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy™
- Remoxy Meets Primary Endpoint in Pivotal Phase III Study
- Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics’ Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
- New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
- Javelin Pharmaceuticals Launches Dyloject(R) in UK
- Results from Biovitrum\'s Phase II Clinical Trial of Novel Pain Treatment is expected to be presented in beginning of second quarter 2008
- New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
- NicOx completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update
- QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy
- Javelin Pharmaceuticals Announces Successful Dyloject Pivotal US Phase 3 Trial Top-Line Results at New York City Analyst Day
- Successful transdermal oxycodone clinical trial results
- Orexo\'s partner Endo announces positive results from interim analysis of Rapinyl phase III clinical trial
- Endo Announces Positive Results From Interim Analysis of RAPINYL(TM) Phase III Clinical Trial
- Dynogen Announces Positive Results in Phase 2 IBS-d Study
- Adolor Initiates Phase 2a Study of Delta Agonist ADL5859 in Neuropathic Pain
- Kalypsys Initiates Second Phase I Clinical Trial of Topical iNOS Inhibitor
- DURECT Announces Positive ELADUR™ Phase IIa Study Results
- Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
- Collegium Pharmaceutical Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
- Adolor Announces Investigational New Drug Application for Novel Delta Agonist ADL5747
- Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
- Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance™
- Javelin Pharmaceuticals\' Latest Study of Dyloject(TM) Confirms Minimal Effect on Platelet Function, Differentiating Dyloject from Ketorolac and Aspirin
- Javelin Pharmaceuticals\' Latest Study of Dyloject(TM) Confirms Minimal Effect on Platelet Function, Differentiating Dyloject from Ketorolac and Aspirin
- FDA Accepts for Filing the BEMA™ Fentanyl NDA from BioDelivery Sciences
- Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance
- DIAMYD FILES US IND FOR PHASE I TRIAL WITH NOVEL CHRONIC PAIN THERAPY
- SANTOSOLVE REPORTS POSITIVE PHASE II RESULTS IN PATIENTS WITH OSTEOARTHRITIS
- Trophos reaches mid-point of Phase II Clinical Trial of TRO19622 in painful diabetic neuropathy
- EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene and EpiCept NP-1 Cream
- Labopharm Receives FDA Response To Recent Appeal Of Approvable Letter For Once-Daily Tramadol
- Cephalon\'s EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
- Penwest Announces Results of Phase IIa Clinical Study of Nalbuphine ER.
- AKELA PHARMA RECEIVES LETTER FROM THE FDA REGARDING ITS PRE-CLINICAL TOXICOLOGY STUDIES FOR FENTANYL TAIFUN
- Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Tezampanel Demonstrates Compound is Safe and Well-Tolerated
- AVANIR Announces Progress on Zenvia Development
- Transdel Pharmaceuticals Submits to the FDA the Phase 3 Clinical Study of Ketotransdel for the Treatment of Acute Pain
- Medtronic Receives U.S. FDA Approval for New Neurostimulator with Innovative Patient Programmer
- EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
- Neurogen Announces R&D Update
- Sosei Announces Start of AD 923 Phase III Studies in Europe
- Labopharm\'s Once-Daily Tramadol Approved in South Korea and Australia
- St. Jude Medical Receives FDA and CE Mark Approvals of Extended 10-Year Battery Life Claim for Rechargeable Neurostimulator
- DIAMYD RECEIVES FDA APPROVAL TO INITIATE CLINICAL STUDY IN CHRONIC PAIN
- Newron completes enrolment of clinical phase II study with ralfinamide in post-surgical (dental) pain
- Javelin Pharmaceuticals Completes Subject Accrual for all Pharmacokinetic Clinical Studies of PMI-150
- ZARS Pharma Announces Marketing Authorization of Rapydan in Europe
- NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
- Array BioPharma Announces Positive Phase 2 Top-Line Results in Inflammatory Pain Clinical Trial
- Alexza\'s AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
- Alexza\'s AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
- AKELA PHARMA INITIATES ITS FIRST ABUSE DETERRENT OPIOID PHASE I CLINICAL TRIAL
- Rapinyl Receives Swedish Marketing Authorisation
- Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
- Phase II migraine with aura trial fully enrolled
- Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
- Zogenix Announces sumatriptan DosePro NDA Accepted for Filing by FDA
- Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
- Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
- Urigen Announces Early Closure of URG101 Phase II Clinical Trial based on Positive Interim Analysis Results
- Phase III MS Neuropathic Pain Trial Preliminary Results
- DURECT Provides Update on CHRONOGESIC(R) Research Program
- Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
- Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
- St. Jude Medical Receives FDA and CE Mark Approvals for the World\'s Smallest, Longest-Lasting Rechargeable Neurostimulator to Treat Chronic Pain
- Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine
- Pipex Pharmaceuticals’ Oral Flupirtine Receives IND with FDA For Phase II Clinical Trial For Fibromyalgia
- King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment For Pivotal Phase III Clinical Trial Evaluating Acurox
- QRxPharma Releases Successful Phase 3 Study Results for \'Dual Opioid\' Pain Therapy
- Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
- FDA ADVISORY COMMITTEE VOTES IN FAVOR OF APPROVAL OF FOSPROPOFOL DISODIUM INJECTION FOR SEDATION
- New Abbott Study of Investigational Vicodin CR Meets Primary Efficacy Endpoints in Phase III Trial
- POZEN IND and NDA for Treximet(TM) (Sumatriptan/Naproxen Sodium) Transferred to GlaxoSmithKline
